Nuvectis Pharma Q3 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Cash, Cash Equivalents, And Short-term Investments Were $17.2M

Benzinga11-05

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 35.14 percent increase over losses of $(0.37) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481757706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481757706","market":"hk","top_or_hot":-1,"title":"Nuvectis Pharma Q3 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Cash, Cash Equivalents, And Short-term Investments Were $17.2M","media":"Benzinga","content":"<html><body><p>Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 35.14 percent increase over losses of $(0.37) per share from the same period last year.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvectis Pharma Q3 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Cash, Cash Equivalents, And Short-term Investments Were $17.2M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvectis Pharma Q3 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Cash, Cash Equivalents, And Short-term Investments Were $17.2M\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 20:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/24/11/41741129/nuvectis-pharma-q3-2024-gaap-eps-0-24-beats-0-26-estimate-cash-cash-equivalents-and-short-term-inve><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 35.14 percent increase over losses of $(...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/24/11/41741129/nuvectis-pharma-q3-2024-gaap-eps-0-24-beats-0-26-estimate-cash-cash-equivalents-and-short-term-inve\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCT","symbol_name":"Nuvectis Pharma, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/24/11/41741129/nuvectis-pharma-q3-2024-gaap-eps-0-24-beats-0-26-estimate-cash-cash-equivalents-and-short-term-inve","article_id":"2481757706","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481757706","pubTimestamp":1730808379,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 35.14 percent increase over losses of $(0.37) per share from","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVCT":"Nuvectis Pharma, Inc."},"translate_title":"Nuvectis Pharma 2024年第三季度GAAP每股收益(0.24)美元超出预期(0.26)美元，现金、现金等价物和短期投资为1,720万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCT":1},"content_text":"Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 35.14 percent increase over losses of $(0.37) per share from the same period last year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481757706"}